Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

被引:117
作者
Cook, Richard J.
Coleman, Robert
Brown, Janet
Lipton, Allan
Major, Pierre
Hei, Yong Jiang
Saad, Fred
Smith, Matthew R.
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada
[3] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[4] Milton S Hershey Med Ctr, Hershey, PA USA
[5] Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada
[6] McMaster Univ, Dept Med, Hamilton, ON, Canada
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
[8] Univ Montreal, Ctr Hosp, Hop Notre Dame, Montreal, PQ, Canada
关键词
D O I
10.1158/1078-0432.CCR-06-0269
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the relative prognostic value for specific markers of osteoblast and osteoclast activity while controlling for previously reported prognostic variables among men with hormone-refractory metastatic prostate cancer. Experimental Design: The 643 subjects in this report were participants in multicenter randomized controlled trial of zoledronic acid in men with metastatic prostate cancer. All subjects had bone metastases and disease progression despite medical or surgical castration. Relationships between baseline covariates and overall survival were examined by Cox proportional hazard model. Serum bone-specific alkaline phosphatase (BAP) and urinary N-telopeptide were assessed as representative specific markers of osteoblast and osteoclast activity, respectively. Other covariates in the model were age, log prostate-specific antigen, hemoglobin, lactate dehydrogenase, albumin, analgesic use, and Eastern Cooperative Oncology Group performance status. Results: Serum BAP was significantly correlated with urinary N-telopeptide (correlation coefficient = 0.674; 95% confidence interval, 0.628-0.715; P < 0.0001). In univariate analyses, higher levels of serum BAP and urinary N-telopeptide levels were significantly associated with shorter overall survival. After controlling for the other variables, including N-telopeptide, in multivariate models, higher serum BAP levels were consistently associated with shorter survival. In contrast, urinary N-telopeptide levels were not significantly associated with survival in multivariate analyses. Variables retained in the reduced multivariate model were age, log prostate - specific antigen, hemoglobin, lactate dehydrogenase, analgesic use, and BAR Conclusions: Serum BAP significantly correlates with urinary N-telopeptide in men with androgen-independent prostate cancer and bone metastases. In multivariate models, higher levels of serum BAP but not urinary N-telopeptide are associated with shorter overall survival.
引用
收藏
页码:3361 / 3367
页数:7
相关论文
共 12 条
  • [1] Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Brown, JE
    Cook, RJ
    Major, P
    Lipton, A
    Saad, F
    Smith, M
    Lee, KA
    Zheng, M
    Hei, YJ
    Coleman, RE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 59 - 69
  • [2] CLARKE NW, 1993, EUR UROL, V24, P286
  • [3] MORPHOMETRIC EVIDENCE FOR BONE-RESORPTION AND REPLACEMENT IN PROSTATE-CANCER
    CLARKE, NW
    MCCLURE, J
    GEORGE, NJR
    [J]. BRITISH JOURNAL OF UROLOGY, 1991, 68 (01): : 74 - 80
  • [4] Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Coleman, RE
    Major, P
    Lipton, A
    Brown, JE
    Lee, KA
    Smith, M
    Saad, F
    Zheng, M
    Hei, YJ
    Seaman, J
    Cook, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4925 - 4935
  • [5] Fontana A., 2000, Cancer, V88, P2952, DOI 10.1002/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO
  • [6] 2-M
  • [7] Markers of bone turnover in prostate cancer
    Garnero, P
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (03) : 187 - 192
  • [8] Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Halabi, S
    Small, EJ
    Kantoff, PW
    Kattan, MW
    Kaplan, EB
    Dawson, NA
    Levine, EG
    Blumenstein, BA
    Vogelzang, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1232 - 1237
  • [9] Kalbfleisch J. D., 2002, Wiley series in probability and statistics
  • [10] THE MEASUREMENT OF SERUM ALKALINE-PHOSPHATASE IN CLINICAL MEDICINE
    POSEN, S
    DOHERTY, E
    [J]. ADVANCES IN CLINICAL CHEMISTRY, 1981, 22 : 163 - 245